Patents by Inventor Remi Rabot

Remi Rabot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk
    Patent number: 9428510
    Abstract: The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: August 30, 2016
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Anna Kruczynski, Laurent Creancier, El Bachir Kaloun, Karim Bedjeguelal, Rémi Rabot
  • DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk
    Publication number: 20150266880
    Abstract: The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.
    Type: Application
    Filed: July 29, 2013
    Publication date: September 24, 2015
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Anna Kruczynski, Laurent Creancier, El Bachir Kaloun, Karim Bedjeguelal, Rémi Rabot
  • Tri- and tetracyclic pyrazolo[3,4-B]pyridine compounds as antineoplastic agent
    Patent number: 9085575
    Abstract: The present invention relates to compounds of following general formula (I): and to the pharmaceutically acceptable salts of same, the tautomers of same, the stereoisomers or mixture of stereoisomers in any proportions of same, such as a mixture of enantiomers, notably a racemic mixture, as well as to methods for preparing same and uses of same, notably as an antineoplastic agent.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: July 21, 2015
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Rémi Rabot, Karim Bedjeguelal, El Bachir Kaloun, Philippe Schmitt, Nicolas Rahier, Patrice Mayer, Emmanuel Fournier
  • Pyrazolopyridine derivatives as anticancer agent
    Patent number: 8889711
    Abstract: The present invention concerns compounds of following general formula (I): (Formula I) and their pharmaceutically acceptable salts, their method of preparation and their uses, notably as anticancer agent.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: November 18, 2014
    Assignee: Pierre Fabre Medicament
    Inventors: Karim Bedjeguelal, Rémi Rabot, El Bachir Kaloun, Patrice Mayer, Arnaud Marchand, Nicolas Rahier, Philippe Schambel, Hugues Bienayme
  • Substituted pyrazolo[3,4-b]pyridines as medicaments
    Patent number: 8883821
    Abstract: The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: November 11, 2014
    Assignee: Pierre Fabre Medicament
    Inventors: El Bachir Kaloun, Karim Bedjeguelal, Rémi Rabot, Anna Kruczynski, Philippe Schmitt, Michel Perez, Nicolas Rahier
  • TRI - AND TETRACYCLIC PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS ANTINEOPLASTIC AGENT
    Publication number: 20140031362
    Abstract: The present invention relates to compounds of following general formula (I): and to the pharmaceutically acceptable salts of same, the tautomers of same, the stereoisomers or mixture of stereoisomers in any proportions of same, such as a mixture of enantiomers, notably a racemic mixture, as well as to methods for preparing same and uses of same, notably as an antineoplastic agent.
    Type: Application
    Filed: April 12, 2012
    Publication date: January 30, 2014
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Rémi Rabot, Karim Bedjeguelal, El Bachir Kaloun, Philippe Schmitt, Nicolas Rahier, Patrice Mayer, Emmanuel Fournier
  • DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT
    Publication number: 20130172360
    Abstract: The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.
    Type: Application
    Filed: January 27, 2012
    Publication date: July 4, 2013
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: El Bachir Kaloun, Karim Bedjeguelal, Rémi Rabot, Anna Kruczynski, Philippe Schmitt, Michel Perez, Nicolas Rahier
  • Pyrroloquinoline derivatives and their use as protein kinases inhibitors
    Patent number: 8426437
    Abstract: The present invention relates to inhibitors of protein kinases of formula I: which can be used in the treatment of various diseases, notably cancer, inflammation or disorders of the central nervous system. It also relates to pharmaceutical compositions containing the compounds according to the invention and their use in therapy.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: April 23, 2013
    Assignee: Pierre Fabre Medicament
    Inventors: Hugues Bienayme, Antoine Dumoulin, Serge Grisoni, Bachir Kaloun El, Stephane Poigny, Remi Rabot, Rachid Rahali, Eric Tam, Pascaline Klein, Karim Bedjeguelal, Houcine Rahali
  • PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT
    Publication number: 20120245170
    Abstract: The present invention concerns compounds of following general formula (I): (Formula I) and their pharmaceutically acceptable salts, their method of preparation and their uses, notably as anticancer agent.
    Type: Application
    Filed: October 13, 2010
    Publication date: September 27, 2012
    Applicant: Pierre Fabre Medicament
    Inventors: Karim Bedjeguelal, Rémi Rabot, El Bachir Kaloun, Patrice Mayer, Arnaud Marchand, Nicolas Rahier, Philippe Schambel, Hugues Bienayme
  • Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors
    Publication number: 20090042876
    Abstract: The present invention relates to inhibitors of protein kinases of formula I: which can be used in the treatment of various diseases, notably cancer, inflammation or disorders of the central nervous system. It also relates to pharmaceutical compositions containing the compounds according to the invention and their use in therapy.
    Type: Application
    Filed: June 30, 2006
    Publication date: February 12, 2009
    Applicant: Pierre Fabre Medicament
    Inventors: Hugues Bienayme, Antoine Dumoulin, Serge Grisoni, Bachir Kaloun El, Stephane Poigny, Remi Rabot, Rachid Rahali, Eric Tam, Pascaline Klein, Karim Bedjeguelal, Houcine Rahali